Chronic Kidney Disease (CKD) Challenges and New Solutions

PREVALENCE OF CKD ACROSS THE US

CKD MORBIDITY/MORTALITY

Estimated prevalence, CKD, U.S. population, 2015-2030

13.2%

14.4%

16.7%

Current CKD Prevalence for Age >65 yo

44%

SOURCES:

> Hoerger TJ et al., American Journal of Kidney Diseases, March 2015 > Braun LA et al., International Journal of Nephrology and Renovascular Disease 2012:5 151–163 > Centers for Disease Control and Prevention, National Center for Health Statistics. Deaths: Final Date for 2011. www.cdc.gov > U.S. Renal Data System. USROS 2010 Annual Report; 2:219

> 2014 USRDS Annual Data Report; Volume 1 – CKD > Hoerger TJ et al. Am J Kidney Dis. 2015;65(3):403-411, JAMA, SEER Cancer Statistics > United States Renal Data System’s 2010 Annual Data Report and 2011 Annual Data Report. > Braun LA et al., International Journal of Nephrology and Renovascular Disease 2012:5 151–163

> 2013 USRDS Annual Data Report; Volume 2 > 2014 USRDS Annual Data Report; Volume 1 – CKD > Source: U.S. Renal Data System, 2005-2012. http://www.usrds.org/2014/view/v2_02.aspx > Personal communication with Navdeep Tangri, MD, FRCPC; Tangri N et al. JAMA. 2016;315(2):164-174; Lee et al. BMC Health Services Research 2012, 12:252; Viewics analysis

> Personal communication with Navdeep Tangri, MD, FRCPC; Tangri N et al. JAMA. 2016;315(2):164-174; Viewics analysis > JAMA. 2016;315(2):164-174.

Leading cause of death in America9th

mortality ratein the first year of dialysis

23%

CKD patients’ rate of hospital readmissions40% higher

only to heart disease in lifetime incidence risk of morbidity (at age 30 in 2015)

2nd

Heart disease, males* 60.3

Heart disease, females* 55.6

CKD 54.1

Cancer, all sites, males 42.8

Cancer, all sites, both sexes 40.0

Cancer, all sites, females 37.6

HIGH GROWTH RATE

COSTS

SUBOPTIMAL CKD CARE

VIEWICS’ NEW SOLUTION FOR CKD

VIEWICS CKD MANAGEMENTTM

POTENTIAL COST SAVINGS

The incidence of recognized CKD in people ages 65

and older more than doubled between 2000 and 2008.

Approximate Medicare spending forEnd Stage Renal Disease in 2015

$56 billion

$ $$

$$

Approximate Medicare spending per person for hemodialysis patients in 2015

$98,000How much more Medicare renal failure patients cost compared to the average

Medicare population

5x

Patient awareness for those with Stages 1-3 CKD

Renal failure patients who saw a nephrologist in the prior year

10%<

33%Amount of dialysis patients who used the

access port associated with the best outcomes in 2011 (a fistula)

16%

Uses an algorithm that combines laboratory tests, age, and gender to predict a patient’s risk of renal failure

End Stage Renal Disease (ESRD) Risk Score+ + =Age

Validated as accurate in more than

720,000 patients, 30 countries

Viewics is implementing the predictive analytics application to automatically deliver the risk score to clinicians and issue customized, educational reports to patients and clinicians.

Approximate full potential savings for U.S. population of CKD Stage 3 and 4 using Viewics CKD ManagementTM

To learn more visit www.renalrisk.com

Approximate cost savings per Stage 4 patient per year using Viewics CKD ManagementTM

$15B

Incorrect Patient ClassificationViewics CKD ManagementTM can help

rectify misclassification of Stage 4 CKD patients into Stage 3 patients due to

inappropriate staging

$5,600

13.2%Estimated prevalence, CKD, U.S. population

2000 2008

Ontario, Canadawill begin requiring the Risk Score in order to receive reimbursement for late stage CKD beginning in April 2016

30%

stage 1

stage 2

stage 3

stage 4

2015

2020

2030